| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10965643 | Vaccine | 2014 | 7 Pages |
Abstract
RTS,S/AS01 lots formulated from commercial-scale purified antigen bulk batches induced a consistent anti-CS antibody response, and the anti-CS GMT of pooled commercial-scale lots was non-inferior to that of a lot formulated from a pilot-scale antigen bulk batch.
Keywords
QS21CircumsporozoiteSAEGMTSASMPLHBSATPHepatitis B surface antigenSafetyImmunogenicityimmunoglobulin according-to-protocolELISAEnzyme-linked immunosorbent assayConsistencyStatistical Analysis Systemadverse eventSerious adverse eventconfidence intervalMonophosphoryl lipid AMalariaGeometric mean titreChildren
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Rich Umeh, Stephen Oguche, Tagbo Oguonu, Simon Pitmang, Elvis Shu, Jude-Tony Onyia, Comfort A. Daniyam, David Shwe, Abdullahi Ahmad, Erik Jongert, Grégory Catteau, Marc Lievens, Opokua Ofori-Anyinam, Amanda Leach,